Key points are not available for this paper at this time.
Design
Editorial
Answers are grounded in this paper and cite their sources.
Elevated Lp(a) is a recognized causal risk factor for ASCVD, and while current management focuses on controlling traditional risk factors and apheresis for severe cases, novel RNA-targeting therapies are currently in phase III trials.
Lipoprotein(a) (Lp(a)) is a well-recognized causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis. There are ongoing challenges with screening and management in primary and secondary prevention; however, future recommendations for clinical practice await the outcomes of clinical trials that are in progress.
No takes yet. Share an insight, caveat, or question.
Barbir et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: